Skip to main content
Premium Trial:

Request an Annual Quote

Wash U Genome Institute Receives $25M Endowment

NEW YORK (GenomeWeb) – Washington University in St. Louis today announced that it has received a $25 million endowment from James and Elizabeth McDonnell for The Genome Institute at its medical school.

The gift will fund research in the genetic origins of diseases like autism and cancer as well as diagnosis and treatment for those diseases, the school said in a statement. Washington University will rename the institute The Elizabeth H. and James S. McDonnell III Genome Institute.

"Libby and Jim McDonnell have championed the medical school for many years and this gift demonstrates their exceptional dedication to ensuring our success in many important areas," Larry Shapiro, dean of the School of Medicine, said in a statement.

The McDonnells previously endowed a professorship and provided funding for a pediatric research building at Washington University.

The Genome Institute played a key role in the Human Genome Project and today is one of three large-scale genome centers in the US funded by the National Institutes of Health.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.